Chronic Illness Digital Twins™: How It Works
- 7 days ago
- 9 min read
A Predictive Modeling Framework for Complex Disease Systems
By Cynthia Adinig
Key Findings and Summary
Chronic illnesses are not static conditions. They are dynamic, multi-system processes shaped by symptom sequencing, physiologic instability, environmental exposure, and intervention timing. Yet most healthcare systems still rely on episodic clinical snapshots that fail to capture how these illnesses actually behave over time. This creates a major modeling gap in both care delivery and prevalence estimation.
The Chronic Illness Digital Twins™ framework developed by CYNAERA introduces a predictive modeling architecture designed to simulate complex disease systems in real time. By integrating symptom progression, environmental load, treatment response, baseline risk, and dynamic instability patterns, the framework enables simulation of flare trajectories, stability windows, and intervention sensitivity across both individual patients and broader populations.
Long COVID serves as a primary validation example because of its relapsing-remitting nature, multi-system burden, and unusually high variability across patients. However, the framework is designed for application across a broader infection-associated chronic condition cluster, including ME/CFS, dysautonomia, MCAS, hypermobile Ehlers-Danlos syndrome, fibromyalgia, small fiber neuropathy, Sjögren’s, chronic Lyme or PTLD, and pediatric post-infectious conditions such as PANS and PANDAS (Adinig, 2025a; Adinig, 2026a).
This broader context matters because prevalence is not shaped by biology alone. It is also shaped by whether a condition is legible to the systems tasked with identifying and counting it. Conditions with obvious vitals disruption, acute events, or measurable instability are more likely to be partially captured, even when misdiagnosed. Conditions defined by delayed crashes, post-exertional worsening, cognitive dysfunction, sensory overload, or fluctuating functional collapse are far more likely to be missed, psychologized, or fragmented across symptom codes. In this sense, clinical invisibility acts as a prevalence distortion force across the infection-associated chronic condition landscape (Adinig, 2025b).
Under the CYNAERA US-CCUC™ correction framework, the national burden of these conditions is substantially higher than legacy public estimates suggest. Corrected U.S. ranges currently include approximately 48.5 to 64.6 million people with Long COVID, 18 to 26 million with ME/CFS, 20 to 28 million with dysautonomia, 20 to 28 million with MCAS, 12 to 18 million with hypermobile Ehlers-Danlos syndrome, 13 to 18 million with fibromyalgia, 6.5 to 8.5 million with small fiber neuropathy, 7 to 10 million with Sjögren’s, 5 to 7 million with chronic Lyme or PTLD, and an estimated 2 to 4 million children with PANS or PANDAS, despite only a fraction of that pediatric burden being formally diagnosed (Adinig, 2026a).
After correction for overlap across conditions, CYNAERA’s 2026 model estimates that roughly 75 to 90 million Americans may now be living with at least one infection-associated chronic condition, with approximately 25 to 35 million experiencing overlap across multiple IACCs. In practical terms, this suggests that roughly one in four U.S. adults may now live with an infection-associated chronic condition burden substantial enough to affect health, function, care utilization, or long-term risk modeling (Adinig, 2026a). This prevalence scale is precisely why dynamic modeling matters. A system affecting tens of millions of people cannot be adequately understood through static diagnosis labels or isolated office visits. It requires a modeling framework capable of capturing fluctuation, interaction, and hidden burden over time. Chronic Illness Digital Twins™ is designed to meet that need by shifting chronic disease analysis from reactive classification to predictive infrastructure.
This failure is not only clinical. It is statistical. When disease models rely on healthcare encounters that were never designed to capture fluctuating, delayed, or environmentally triggered disability, prevalence itself becomes distorted. The result is not a small undercount but a structurally biased one, where more clinically visible conditions are more likely to enter datasets and less legible conditions remain hidden despite major functional burden (Adinig, 2025b; Adinig, 2026a).
The Problem: Static Models in a Dynamic Disease Landscape
Healthcare systems are structurally optimized for acute illness. Diagnostic frameworks, reimbursement models, and clinical workflows are built around discrete events rather than continuous physiological processes.
Chronic conditions such as Long COVID and ME/CFS challenge this paradigm. Patients experience:
Non-linear symptom progression
Post-exertional worsening
Environmental sensitivity
Fluctuating autonomic and immune responses
Despite this, most clinical models treat disease as a stable state, leading to misclassification, inconsistent treatment outcomes, and high rates of perceived treatment failure (Iwasaki et al., 2022; Komaroff & Lipkin, 2021). Clinical trials are particularly affected. Variability between participants is often treated as noise rather than signal, obscuring meaningful patterns and reducing statistical power. Current medical modeling is optimized for acute disease, not dynamic systems.
Framework Architecture: Modeling Disease as a Dynamic System
The Chronic Illness Digital Twins™ framework constructs a continuously updating representation of patient state using multi-source inputs.
Core Inputs
Symptom trajectory over time
Environmental exposure (PM2.5, humidity, mold risk, temperature variability)
Intervention timing and response
Baseline physiological and comorbidity profile
Integrated CYNAERA Modules
SymCas™: Temporal sequencing and persistence weighting of symptoms
VitalGuard™: Environmental trigger modeling and exposure scoring
NeuroVerse™: Neuroimmune and autonomic pattern mapping
Core Outputs
Flare Probability Score (FPS)
Stability Index (SI)
Intervention Sensitivity Profile (ISP)
These outputs are recalculated continuously, allowing the system to simulate near-term and medium-term disease states.
Digital Twin Feedback Loop
Inputs → Processing → Outputs → Adaptive Adjustment
Symptoms → SymCas™
Environment → VitalGuard™
Neuro signals → NeuroVerse™
Outputs:
FPS → triggers intervention adjustment
SI → informs pacing thresholds
ISP → refines treatment selection
Then loop back.
Mathematical Representation (Simplified Model Layer)
Patient State Score =(alpha x Symptom History) + (beta x Environmental Exposure) + (gamma x Intervention Response) + (delta x Baseline Risk)
Where:
Symptom History = weighted symptom activity across prior time periods
Environmental Exposure = current trigger burden, such as air quality, humidity, mold risk, or temperature instability
Intervention Response = the effect of treatment, pacing, medication, or supportive care on current stability
Baseline Risk = the patient’s underlying physiological vulnerability, comorbidities, and severity profile
Alpha, beta, gamma, and delta = weighting values that determine how strongly each factor influences the final state score
Derived Output: Flare Probability Score
FPS = (Persistence Score x Pattern Match Score) + Environmental Load Score - Stabilization Effect
Where:
Sₚₑᵣₛᵢₛₜₑₙcₑ = how long and consistently symptoms have been present
PatternMatch = how closely current symptoms match known flare patterns
E_load = total environmental trigger burden (air quality, humidity, mold risk, etc.)
I_stabilization = the degree to which interventions are reducing instability
This structure allows the model to:
Detect early destabilization signals
Differentiate between treatment failure and external trigger amplification
Simulate outcomes under altered conditions
Importantly, the model does not assume linear progression. Instead, it captures oscillation, threshold effects, and delayed responses observed in chronic illness populations.
Modeled Example: Divergence in Long COVID Outcomes
Two patients with comparable Long COVID diagnoses:
Variable | Patient A | Patient B |
Baseline severity | Moderate | Moderate |
Treatment | Pacing + LDN | Pacing + LDN |
Age | 34 | 36 |
Environmental Exposure (7-Day Average)
Metric | Patient A | Patient B |
PM2.5 | 8 µg/m³ | 22 µg/m³ |
Humidity | 45% | 68% |
Mold Risk Index | Low | High |
Symptom Persistence Score (SymCas™)
Metric | Patient A | Patient B |
Fatigue persistence | 0.6 | 0.85 |
Cognitive impairment | 0.5 | 0.8 |
Autonomic instability | 0.55 | 0.9 |
Model Output
Output | Patient A | Patient B |
Flare Probability Score | 0.42 | 0.81 |
Stability Index | 0.68 | 0.29 |
Intervention Sensitivity | Moderate | Low |
Interpretation
Patient B’s elevated environmental load and higher symptom persistence create a compounded instability effect. Despite identical treatment, their system remains in a near-flare state. The divergence is not random. It is structurally predictable. The issue is not treatment failure. It is context mismatch. This distinction has significant implications for both clinical care and research design.
Why It Matters
Clinical Trials
Digital twins reduce noise by identifying high-variability participants and enabling stratified modeling, improving trial efficiency and outcome clarity (Collins et al., 2023).
Healthcare Systems
Predictive modeling enables early intervention, reducing emergency care utilization and improving patient stability.
Pharmaceutical Development
Simulation across patient archetypes allows for more precise targeting of therapies and identification of responder subgroups.
Public Health and Government
Population-level modeling enables forecasting of disease burden and environmental risk interaction, supporting policy development.
Insurance and Risk Modeling
Early detection of destabilization reduces high-cost care events and supports proactive care strategies.
Conclusion
Chronic illness is one of the great modeling failures of modern medicine. Health systems still attempt to interpret dynamic, relapsing, multi-system disease through tools built for acute events, isolated encounters, and static classification. That mismatch has consequences. It distorts prevalence, weakens research, delays care, and leaves millions of patients functionally invisible even when they are severely impaired. The Chronic Illness Digital Twins™ framework offers a different path. Rather than asking medicine to work harder within an outdated structure, it introduces a new structure entirely, one capable of modeling instability, context, and change over time. In this framework, disease is not treated as a fixed label. It is treated as a living system shaped by physiology, environment, timing, and interaction.
Long COVID makes the need for this shift impossible to ignore. Its scale, variability, and overlap with other infection-associated chronic conditions have exposed just how inadequate static models have become. But Long COVID is not the endpoint of this work. It is the opening signal of a much larger transformation. The future of chronic disease infrastructure will belong to systems that can anticipate rather than react, simulate rather than merely document, and identify invisible burden before it becomes institutional crisis. Chronic Illness Digital Twins™ was built for that future.
Market Application and Licensing
The Chronic Illness Digital Twins™ framework is available through CYNAERA Market for cross-sector deployment.
Available licensing pathways include:
Research and academic licensing
Clinical integration via API
Government and public health modeling systems
Enterprise dashboards for health systems and insurers
Custom implementations can integrate additional CYNAERA modules to support condition-specific or region-specific modeling.
CYNAERA Framework Papers
This paper draws on a defined subset of CYNAERA Institute white papers that establish the methodological and analytical foundations of CYNAERA’s frameworks. These publications provide deeper context on prevalence reconstruction, remission, combination therapies and biomarker approaches. Our Long COVID Library is also a great resource.
Author’s Note:
All insights, frameworks, and recommendations in this written material reflect the author's independent analysis and synthesis. References to researchers, clinicians, and advocacy organizations acknowledge their contributions to the field but do not imply endorsement of the specific frameworks, conclusions, or policy models proposed herein. This information is not medical guidance.
Patent-Pending Systems
Bioadaptive Systems Therapeutics™ (BST) and all affiliated CYNAERA frameworks, including Pathos™, VitalGuard™, CRATE™, SymCas™, TrialSim™, and BRAGS™, are protected under U.S. Provisional Patent Application No. 63/909,951.
Licensing and Integration
CYNAERA partners with universities, research teams, federal agencies, health systems, technology companies, and philanthropic organizations. Partners can license individual modules, full suites, or enterprise architecture. Integration pathways include research co-development, diagnostic modernization projects, climate-linked health forecasting, and trial stabilization for complex cohorts. You can get basic licensing here at CYNAERA Market.
Support structures are available for partners who want hands-on implementation, long-term maintenance, or limited-scope pilot programs.
About the Author
Cynthia Adinig is a researcher, health policy advisor, author, and patient advocate. She is the founder of CYNAERA and creator of the patent-pending Bioadaptive Systems Therapeutics (BST)™ platform. She serves as a PCORI Merit Reviewer, Board Member at Solve M.E., and collaborator with Selin Lab for t cell research at the University of Massachusetts.
Cynthia has co-authored research with Harlan Krumholz, MD, Dr. Akiko Iwasaki, and Dr. David Putrino, though Yale’s LISTEN Study, advised Amy Proal, PhD’s research group at Mount Sinai through its patient advisory board, and worked with Dr. Peter Rowe of Johns Hopkins on national education and outreach focused on post-viral and autonomic illness. She has also authored a Milken Institute essay on AI and healthcare, testified before Congress, and worked with congressional offices on multiple legislative initiatives. Cynthia has led national advocacy teams on Capitol Hill and continues to advise on chronic-illness policy and data-modernization efforts.
Through CYNAERA, she develops modular AI platforms, including the IACC Progression Continuum™, Primary Chronic Trigger (PCT)™, RAVYNS™, and US-CCUC™, that are made to help governments, universities, and clinical teams model infection-associated conditions and improve precision in research and trial design. US-CCUC™ prevalence correction estimates have been used by patient advocates in congressional discussions related to IACC research funding and policy priorities. Cynthia has been featured in TIME, Bloomberg, USA Today, and other major outlets, for community engagement, policy and reflecting her ongoing commitment to advancing innovation and resilience from her home in Northern Virginia.
Cynthia’s work with complex chronic conditions is deeply informed by her lived experience surviving the first wave of the pandemic, which strengthened her dedication to reforming how chronic conditions are understood, studied, and treated. She is also an advocate for domestic-violence prevention and patient safety, bringing a trauma-informed perspective to her research and policy initiatives.
References
Adinig, C. (2025a). The pathophysiology of infection-associated chronic conditions. CYNAERA Institute.
Adinig, C. (2025b). SILENZR™ and the structural invisibility of chronic illness data. CYNAERA Institute.
Adinig, C. (2026a). Corrected U.S. prevalence estimates for infection-associated chronic conditions: 2026 model update. CYNAERA Institute.
Davis, H. E., McCorkell, L., Vogel, J. M., and Topol, E. J. (2023). Long COVID: major findings, mechanisms and recommendations. Nature Reviews Microbiology, 21(3), 133-146.
Efthimiou, O., Mallett, S., Hyde, C., Riley, R. D., Debray, T. P. A., and Collins, G. S. (2024). Developing clinical prediction models: a step-by-step guide. BMJ, 386, e078276.
Komaroff, A. L., and Lipkin, W. I. (2021). Insights from myalgic encephalomyelitis/chronic fatigue syndrome may help unravel the pathogenesis of postacute COVID-19 syndrome. Trends in Molecular Medicine, 27(9), 895-906.
Klein, J., Wood, J., Jaycox, J. R., Dhodapkar, R. M., Lu, P., Gehlhausen, J. R., Tabacof, L., Malik, A. A., and others. (2023). Distinguishing features of Long COVID identified through immune profiling. Nature, 623, 139-148.
Comments